Unichem Laboratories Ltd

Unichem Laboratories Ltd

₹ 535 0.48%
21 Jun - close price
About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

Key Points

Therapeutic Areas
The company manufactures a wide range of APIs and pharmaceutical formulations as branded and simple generics. Its products cater to diverse range of therapeutic areas, such as cardiology, gastroenterology, diabetology, psychiatry, neurology and others. [1]

  • Market Cap 3,767 Cr.
  • Current Price 535
  • High / Low 616 / 365
  • Stock P/E
  • Book Value 336
  • Dividend Yield 0.00 %
  • ROCE 0.69 %
  • ROE -0.88 %
  • Face Value 2.00

Pros

  • Company has reduced debt.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 7.64% over past five years.
  • Company has a low return on equity of -2.23% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
274 298 291 311 370 310 329 302 402 423 416 434 432
255 300 284 313 302 311 347 345 386 395 407 396 406
Operating Profit 19 -2 6 -1 68 -1 -18 -43 16 28 9 38 25
OPM % 7% -1% 2% -0% 18% -0% -6% -14% 4% 7% 2% 9% 6%
8 16 3 15 14 8 4 16 -28 9 6 79 -119
Interest 2 1 2 1 2 3 5 4 6 6 7 6 5
Depreciation 22 22 22 23 23 25 28 31 30 29 29 28 27
Profit before tax 3 -9 -16 -11 58 -21 -47 -61 -47 2 -22 84 -126
Tax % 114% -27% 17% -24% -23% -13% -50% -4% 6% 132% -12% -0% -3%
-0 -11 -13 -14 71 -23 -71 -64 -44 -1 -24 84 -129
EPS in Rs -0.06 -1.63 -1.82 -2.00 10.15 -3.32 -10.04 -9.08 -6.29 -0.10 -3.48 11.93 -18.37
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,081 1,133 1,202 1,333 698 815 1,180 1,104 1,235 1,270 1,343 1,705
906 956 1,100 1,169 738 942 1,254 1,153 1,144 1,198 1,389 1,605
Operating Profit 174 178 101 164 -41 -128 -74 -49 91 72 -46 100
OPM % 16% 16% 8% 12% -6% -16% -6% -4% 7% 6% -3% 6%
13 83 20 15 184 2,735 91 91 50 47 -0 -26
Interest 3 3 3 3 3 8 8 8 5 6 17 23
Depreciation 38 46 41 39 44 51 67 82 84 91 113 113
Profit before tax 146 212 77 137 97 2,548 -58 -48 51 22 -176 -62
Tax % 22% 20% 3% 21% -12% 0% 59% -25% 33% -50% -15% -14%
113 169 75 108 109 2,545 -24 -60 34 33 -202 -70
EPS in Rs 12.52 18.68 8.31 11.90 11.96 361.82 -3.38 -8.55 4.87 4.70 -28.72 -10.01
Dividend Payout % 36% 43% 24% 17% 25% 1% -118% -47% 82% 85% -14% 0%
Compounded Sales Growth
10 Years: 4%
5 Years: 8%
3 Years: 11%
TTM: 27%
Compounded Profit Growth
10 Years: %
5 Years: 8%
3 Years: %
TTM: 88%
Stock Price CAGR
10 Years: 10%
5 Years: 25%
3 Years: 19%
1 Year: 45%
Return on Equity
10 Years: 13%
5 Years: -2%
3 Years: -2%
Last Year: -1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 18 18 18 18 18 14 14 14 14 14 14 14
Reserves 709 798 849 936 1,045 2,666 2,606 2,517 2,543 2,604 2,421 2,348
27 26 22 36 98 151 200 206 119 349 314 248
318 302 264 283 359 359 323 407 436 351 444 559
Total Liabilities 1,073 1,145 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,169
448 419 416 403 491 578 810 870 884 990 1,257 1,196
CWIP 132 91 123 237 250 238 92 330 568 494 147 123
Investments 39 11 41 14 14 901 926 550 392 264 2 1
454 623 574 620 766 1,473 1,313 1,395 1,269 1,571 1,787 1,849
Total Assets 1,073 1,145 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,169

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
171 87 78 112 68 -112 -328 20 33 -260 -85 17
-118 36 -52 -85 -132 1,648 -286 -36 -66 100 241 50
-51 -95 -51 -33 59 -881 -2 -62 -121 191 -81 -106
Net Cash Flow 1 28 -25 -7 -4 655 -616 -78 -154 32 75 -39

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 70 63 58 60 165 124 135 129 74 142 160 131
Inventory Days 132 192 171 184 397 278 278 374 518 527 414 387
Days Payable 145 142 114 131 297 230 182 236 202 161 193 164
Cash Conversion Cycle 57 113 116 113 265 172 231 267 390 508 382 353
Working Capital Days 59 95 89 94 225 200 227 217 194 277 273 218
ROCE % 20% 19% 9% 15% 9% 128% -2% -2% 2% 1% -5%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
50.93% 50.93% 50.93% 50.93% 50.93% 50.94% 50.94% 50.94% 50.94% 70.21% 70.22% 70.22%
1.54% 1.53% 1.45% 1.47% 1.50% 1.71% 1.56% 1.70% 1.62% 0.83% 0.84% 0.90%
9.09% 9.09% 9.30% 9.59% 9.53% 8.70% 8.21% 8.15% 9.65% 10.00% 10.46% 11.26%
38.43% 38.44% 38.32% 38.01% 38.04% 38.67% 39.31% 39.21% 37.80% 18.95% 18.47% 17.63%
No. of Shareholders 34,25833,89235,31333,55732,66629,57330,61829,41826,64221,58420,87721,171

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls